Diagnostics (Jul 2022)

Cytology and High-Risk Human Papillomavirus Test for Cervical Cancer Screening Assessment

  • Frederik A. Stuebs,
  • Martin C. Koch,
  • Anna K. Dietl,
  • Werner Adler,
  • Carol Geppert,
  • Arndt Hartmann,
  • Antje Knöll,
  • Matthias W. Beckmann,
  • Grit Mehlhorn,
  • Carla E. Schulmeyer,
  • Paul Gass

DOI
https://doi.org/10.3390/diagnostics12071748
Journal volume & issue
Vol. 12, no. 7
p. 1748

Abstract

Read online

Background: A new nationwide screening strategy was implemented in Germany in January 2020. No data are available for women referred to certified dysplasia units for secondary clarification after primary diagnosis by a local physician. We therefore investigated combined testing with Papanicolaou smears and high-risk human papillomavirus (hrHPV) and compared the data with the final histological findings. Methods: Between January 2015 and October 2020, all referred women who underwent colposcopy of the uterine cervix in our certified dysplasia unit were included. Cytology findings were classified using the Munich III nomenclature. Results: A total of 3588 colposcopies were performed in 3118 women, along with Pap smear and hrHPV co-testing, followed by histology. Women with Pap II-p (ASC-US) and a positive hrHPV co-test had a 22.4% risk for cervical intraepithelial neoplasia (CIN) 3/high-grade squamous intraepithelial lesion (HSIL). The risk of CIN 3/HSIL was 83.8% in women with Pap IVa-p (HSIL) and a positive hrHPV co-test. A positive hrHPV co-test increased the risk for HSIL+ (OR 5.942; 95% CI, 4.617 to 7.649; p < 0.001) as compared to a negative hrHPV co-test. Conclusions: The accuracy of Pap smears is comparable with the screening results. A positive hrHPV test increases the risk for HSIL+ fivefold. Colposcopy is necessary to diagnose HSIL+ correctly.

Keywords